vs
GRANITE CONSTRUCTION INC（GVA）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
GRANITE CONSTRUCTION INC的季度营收约是Revvity的1.2倍（$912.5M vs $772.1M），Revvity净利率更高（12.7% vs -4.0%，领先16.7%），GRANITE CONSTRUCTION INC同比增速更快（30.4% vs 5.9%），过去两年Revvity的营收复合增速更高（9.0% vs -8.2%）
Granite Construction Inc.是美国民用建筑企业及建筑骨料生产商，为标普600指数成分股，创始地及总部位于加利福尼亚州沃森维尔，是Granite Construction Company的母公司。公司主营重型民用建筑承包与建筑骨料生产，在美国西部多州持有或租赁采石场，主要开采砂、砾石、碎石等产品。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
GVA vs RVTY — 直观对比
营收规模更大
GVA
是对方的1.2倍
$772.1M
营收增速更快
GVA
高出24.6%
5.9%
净利率更高
RVTY
高出16.7%
-4.0%
两年增速更快
RVTY
近两年复合增速
-8.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $912.5M | $772.1M |
| 净利润 | $-36.4M | $98.4M |
| 毛利率 | 11.2% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | -4.0% | 12.7% |
| 营收同比 | 30.4% | 5.9% |
| 净利润同比 | -23.9% | 3.9% |
| 每股收益（稀释后） | $-0.96 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GVARVTY
| Q1 26 | $912.5M | — | ||
| Q4 25 | $1.2B | $772.1M | ||
| Q3 25 | $1.4B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $699.5M | $664.8M | ||
| Q4 24 | $977.3M | $729.4M | ||
| Q3 24 | $1.3B | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润GVARVTY
| Q1 26 | $-36.4M | — | ||
| Q4 25 | $52.0M | $98.4M | ||
| Q3 25 | $102.9M | $46.7M | ||
| Q2 25 | $71.7M | $53.9M | ||
| Q1 25 | $-33.7M | $42.2M | ||
| Q4 24 | $41.5M | $94.6M | ||
| Q3 24 | $79.0M | $94.4M | ||
| Q2 24 | $36.9M | $55.4M |
毛利率GVARVTY
| Q1 26 | 11.2% | — | ||
| Q4 25 | 14.4% | — | ||
| Q3 25 | 18.2% | 53.6% | ||
| Q2 25 | 17.7% | 54.5% | ||
| Q1 25 | 12.0% | 56.5% | ||
| Q4 24 | 15.4% | — | ||
| Q3 24 | 15.9% | 56.3% | ||
| Q2 24 | 15.2% | 55.7% |
营业利润率GVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 6.4% | 14.5% | ||
| Q3 25 | 10.0% | 11.7% | ||
| Q2 25 | 9.2% | 12.6% | ||
| Q1 25 | -5.7% | 10.9% | ||
| Q4 24 | 6.2% | 16.3% | ||
| Q3 24 | 8.2% | 14.3% | ||
| Q2 24 | 7.9% | 12.4% |
净利率GVARVTY
| Q1 26 | -4.0% | — | ||
| Q4 25 | 4.5% | 12.7% | ||
| Q3 25 | 7.2% | 6.7% | ||
| Q2 25 | 6.4% | 7.5% | ||
| Q1 25 | -4.8% | 6.4% | ||
| Q4 24 | 4.2% | 13.0% | ||
| Q3 24 | 6.2% | 13.8% | ||
| Q2 24 | 3.4% | 8.0% |
每股收益（稀释后）GVARVTY
| Q1 26 | $-0.96 | — | ||
| Q4 25 | $1.23 | $0.86 | ||
| Q3 25 | $1.98 | $0.40 | ||
| Q2 25 | $1.42 | $0.46 | ||
| Q1 25 | $-0.77 | $0.35 | ||
| Q4 24 | $0.99 | $0.77 | ||
| Q3 24 | $1.57 | $0.77 | ||
| Q2 24 | $0.76 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $265.7M | $919.9M |
| 总债务越低越好 | $1.2B | — |
| 股东权益账面价值 | $1.1B | $7.3B |
| 总资产 | $3.8B | $12.2B |
| 负债/权益比越低杠杆越低 | 1.15× | — |
8季度趋势，按日历期对齐
现金及短期投资GVARVTY
| Q1 26 | $265.7M | — | ||
| Q4 25 | $600.2M | $919.9M | ||
| Q3 25 | $547.2M | $931.4M | ||
| Q2 25 | $385.3M | $991.8M | ||
| Q1 25 | $422.8M | $1.1B | ||
| Q4 24 | $585.6M | $1.2B | ||
| Q3 24 | $472.4M | $1.2B | ||
| Q2 24 | $377.2M | $2.0B |
总债务GVARVTY
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $740.4M | — | ||
| Q1 25 | $739.7M | — | ||
| Q4 24 | $739.0M | — | ||
| Q3 24 | $738.6M | — | ||
| Q2 24 | $738.9M | — |
股东权益GVARVTY
| Q1 26 | $1.1B | — | ||
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.1B | $7.6B | ||
| Q1 25 | $993.5M | $7.6B | ||
| Q4 24 | $1.0B | $7.7B | ||
| Q3 24 | $1.0B | $7.9B | ||
| Q2 24 | $931.7M | $7.9B |
总资产GVARVTY
| Q1 26 | $3.8B | — | ||
| Q4 25 | $4.0B | $12.2B | ||
| Q3 25 | $4.1B | $12.1B | ||
| Q2 25 | $3.1B | $12.4B | ||
| Q1 25 | $2.9B | $12.4B | ||
| Q4 24 | $3.0B | $12.4B | ||
| Q3 24 | $3.1B | $12.8B | ||
| Q2 24 | $2.9B | $13.4B |
负债/权益比GVARVTY
| Q1 26 | 1.15× | — | ||
| Q4 25 | 1.14× | — | ||
| Q3 25 | 1.16× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.74× | — | ||
| Q4 24 | 0.73× | — | ||
| Q3 24 | 0.73× | — | ||
| Q2 24 | 0.79× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流GVARVTY
| Q1 26 | — | — | ||
| Q4 25 | $179.3M | $182.0M | ||
| Q3 25 | $284.2M | $138.5M | ||
| Q2 25 | $1.8M | $134.3M | ||
| Q1 25 | $3.6M | $128.2M | ||
| Q4 24 | $172.8M | $174.2M | ||
| Q3 24 | $261.5M | $147.9M | ||
| Q2 24 | $-2.0M | $158.6M |
自由现金流GVARVTY
| Q1 26 | — | — | ||
| Q4 25 | $128.8M | $161.8M | ||
| Q3 25 | $257.5M | $120.0M | ||
| Q2 25 | $-27.0M | $115.5M | ||
| Q1 25 | $-28.6M | $112.2M | ||
| Q4 24 | $144.6M | $149.8M | ||
| Q3 24 | $220.2M | $125.6M | ||
| Q2 24 | $-41.0M | $136.6M |
自由现金流率GVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 11.0% | 21.0% | ||
| Q3 25 | 18.0% | 17.2% | ||
| Q2 25 | -2.4% | 16.0% | ||
| Q1 25 | -4.1% | 16.9% | ||
| Q4 24 | 14.8% | 20.5% | ||
| Q3 24 | 17.3% | 18.4% | ||
| Q2 24 | -3.8% | 19.7% |
资本支出强度GVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 4.3% | 2.6% | ||
| Q3 25 | 1.9% | 2.6% | ||
| Q2 25 | 2.6% | 2.6% | ||
| Q1 25 | 4.6% | 2.4% | ||
| Q4 24 | 2.9% | 3.4% | ||
| Q3 24 | 3.2% | 3.3% | ||
| Q2 24 | 3.6% | 3.2% |
现金转化率GVARVTY
| Q1 26 | — | — | ||
| Q4 25 | 3.45× | 1.85× | ||
| Q3 25 | 2.76× | 2.97× | ||
| Q2 25 | 0.02× | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | 4.17× | 1.84× | ||
| Q3 24 | 3.31× | 1.57× | ||
| Q2 24 | -0.05× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GVA
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
